Investigational Drug Information for Aplindore
✉ Email this page to a colleague
What is the development status for investigational drug Aplindore?
Aplindore is an investigational drug.
There have been 4 clinical trials for Aplindore.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2009.
The most common disease conditions in clinical trials are Psychomotor Agitation, Parkinson Disease, and Syndrome. The leading clinical trial sponsors are Ligand Pharmaceuticals, Neurogen Corporation, and [disabled in preview].
Summary for Aplindore
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 305 |
| WIPO Patent Applications | 207 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 2 (2009-02-01) |
| Vendors | 16 |
Recent Clinical Trials for Aplindore
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome | Neurogen Corporation | Phase 2 |
| Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease | Neurogen Corporation | Phase 2 |
| The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome | Ligand Pharmaceuticals | Phase 2 |
Clinical Trial Summary for Aplindore
Top disease conditions for Aplindore
Top clinical trial sponsors for Aplindore
US Patents for Aplindore
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
